Valneva’s Lyme Disease Jab Program Gets Pfizer Cash Boost
Through Equity Subscription Agreement
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.
